JNCE
Jounce Therapeutics, Inc. (JNCE)
$1.17
Market is closedMarket is closed – opens on 8 PM, 09 Feb 2023
– opens on 8 PM, 09 Feb 2023
Performance
$1.17
Day's Range
$1.22
$0.5773
52-Week Range
$8.8
| Returns % | |
| 1 month return | 9.35% |
| 3 month return | 41.21% |
| 1 year return | 86.15% |
| 5 year return | 95.08% |
Highlights
| Market Capitalization | 60.7M |
| Book Value | $2.5 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.98 |
| PEG Ratio | 0.0 |
| Wall Street Target Price | 6.0 |
Company Financials
Peers
Analyst Recommendation
based on 13 analysts ratings
Buy
76%
Buy
23%
Hold
0%
Sell
Based on 13 Wall street analysts offering stock ratings for Jounce Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 412.82%Current
$1.17
Target
$6.0
Recommendation Trend
Based on 13 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 10 | 10 | 10 |
| Hold | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 19.46 |
| Price/Book (mrq) | 0.27 |
| Enterprise Value | -82093365 |
| Enterprise Value/Revenue | 1.24 |
| Enterprise Value/Ebitda | 0.63 |
Technicals
| Beta | 0.65 |
| 50 Day MA | 0.99 |
| 200 Day MA | 2.74 |
Institutional Holdings
RTW INVESTMENTS, LLC
9.88%
Deep Track Capital, LP
8.24%
Partner Fund Management LP
7.92%
COWEN AND COMPANY, LLC
7.06%
Orbimed Advisors, LLC
5.67%
BlackRock Inc
5.4%
Company Information
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
| Organization | Jounce Therapeutics, Inc. |
| Employees | 137 |
| CEO | Dr. Richard Murray Ph.D. |
| Industry | Health Technology |
Discover more
Frequently Asked Questions
What is Jounce Therapeutics, Inc. share price today?
Can Indians buy Jounce Therapeutics, Inc. shares?
How can I buy Jounce Therapeutics, Inc. shares from India?
Can Fractional shares of Jounce Therapeutics, Inc. be purchased?
What are the documents required to start investing in Jounce Therapeutics, Inc. stocks?
What are today’s High and Low prices of Jounce Therapeutics, Inc.?
What are today’s traded volumes of Jounce Therapeutics, Inc.?
What is today’s market capitalisation of Jounce Therapeutics, Inc.?
What is the 52 Week High and Low Range of Jounce Therapeutics, Inc.?
How much percentage Jounce Therapeutics, Inc. is down from its 52 Week High?
How much percentage Jounce Therapeutics, Inc. is up from its 52 Week low?
What are the historical returns of Jounce Therapeutics, Inc.?
Who is the Chief Executive Officer (CEO) of Jounce Therapeutics, Inc.?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*